Send me real-time posts from this site at my email
Wild Tiger Trading

Trading List: Dec. 11 - Updates & Analyst Actions - SGMO, TGTX

$SGMO, $TGTX - On our trading list with news today or analyst comments with our opinion & trade ideas.

WHAT A DAY for these 2 picks of ours! SGMO up over 50% and TGTX (Our Top Pick) up over 40% on Thursday !!!!

Sangamo and Pfizer this week reported good results on their hemophilia A drug trial. Thursday Sangamo jumped as it and other names in the 'gene therapy' area caught fire.

Our Take: SGMO is on our trading list and will be added to the favorites list soon. We would not chase it, but would accumulate some on dips.

TG Therapeutics price target raised to $61 from $38 at H.C. Wainwright

H.C. Wainwright analyst Edward White raised the firm's price target on TG Therapeutics to $61 from $38 and keeps a Buy rating on the shares after the company announced positive top-line results from the Phase 3 ULTIMATE I and II trials. Both studies met their primary endpoint, demonstrating a statistically significant reduction in annualized relapse rate following 96 weeks of therapy, White tells investors in a research note. The analyst does not expect safety to be an issue in the Phase 3 studies. For ublituximab in multiple sclerosis, he estimates sales of $36M in 2022 and $601M in 2028.

TG Therapeutics price target raised to $70 from $65 at Evercore ISI

Evercore ISI analyst Joshua Schimmer raised the firm's price target on TG Therapeutics to $70 from $65 and keeps an Outperform rating on the shares after the company announced that two Phase 3 studies evaluating ublituximab compared to teriflunomide in patients with relapsing forms of multiple sclerosis both met their primary endpoint. The data give TG Therapeutics "a clear differentiating message" of offering strong efficacy and a shorter infusion time compared to Ocrevus, the analyst said.

Our Take:  TGTX is our top pick. What a day! Up 40% on the MS trial data being released. Very strong efficacy and results for MS in their two Phase 3 studies. This will remain our top pick as we also remind our readers they have other drugs in Phase 3 that are also doing very well.

$TGTX, TG Therapeutics, Inc. / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so).

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.


Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue